

NOROVIRUS & ROTAVIRUS VACCINES FOR THE WORLD

4-6 June 2018, CHUV, University of Lausanne, Lausanne, Switzerland

SECOND CIRCULAR AND PROVISIONAL CONFERENCE PROGRAMME FOR NRW 2018

Rotaviruses (RV) and Noroviruses (NoV) are the most common causes of severe acute gastroenteritis (AGE) in children. It is generally accepted that RV causes severe AGE in a higher proportion of cases compared with NoV.

Globally, norovirus is associated with approximately one-fifth of all diarrhea cases, with similar prevalence in both children and adults, and is estimated to cause over 200,000 deaths annually in developing countries. Norovirus is an important pathogen in a number of high-priority domains: it is the most common cause of diarrheal episodes globally, the principal cause of foodborne disease outbreaks in the United States, a key health care-acquired infection, a common cause of travel-associated diarrhea, and a bane for deployed military troops. Partly as a result of this ubiquity and burden across a range of different populations, identifying target groups and strategies for intervention has been challenging. And, on top of the breadth of this public health problem, there remain important gaps in scientific knowledge regarding norovirus, especially with respect to disease in low-income settings. Many pathogens can cause acute gastroenteritis. Historically, rotavirus was the most common cause of severe disease in young children globally. Now, vaccines are available for rotavirus and are universally recommended by the World Health Organization. In countries with effective rotavirus vaccination programs, disease due to that pathogen has decreased markedly, but norovirus persists and is now the most common cause of pediatric gastroenteritis requiring medical attention. However, the data supporting the precise role of norovirus in low- and middle-income settings are sparse. With vaccines in the pipeline, addressing these and other important knowledge gaps is increasingly pressing.

The global health community is beginning to gain an understanding of the global burden of norovirus-associated disease, which appears to have significant burden in both developed- and developing-country populations. Of particular importance is the growing recognition of norovirus as a leading cause of gastroenteritis and diarrhea in countries where rotavirus vaccine has been introduced. While not as severe as rotavirus disease, the sheer number of norovirus infections not limited to early childhood makes norovirus a formidable global health problem. Multiple vaccine strategies, mostly relying on virus-like particle antigens, are under development and have demonstrated proof of efficacy in human challenge studies. Several are entering phase 2 clinical development. Norovirus vaccine development challenges include, but are not limited to: valency, induction of adequate immune responses in pediatric and elderly populations, and potential for vaccine-strain mismatch. Given current strategies and global health interest, the outlook for a norovirus vaccine is promising. Because a norovirus vaccine is expected to have a dual market in both developed and developing countries, there would likely be scale-up advantages for commercial development and global distribution. Combination with or expression by another enteric pathogen, such as rotavirus, could also enhance uptake of a norovirus vaccine.

NRW 2018 will offer a new forum for researchers to focus on an update of progress with rotavirus vaccines and developments in the research and ultimate implementation of norovirus vaccines.

Abstracts for both oral and poster presentation are called for. Abstracts should be sent directly to the NRW 2018 Secretariat (John Herriot at Meetings Management to email address: jherriot@meetingsmgmt.u-net.com).

SCIENTIFIC ADVISORY PANEL

Timo Vesikari (*University of Tampere, Finland*)

Sean Tucker (*Vaxart Inc., South San Francisco, California, USA*)


Bernd Benninghoff (*GSK Biologicals, Wavre, Belgium*)

Daniel Cohen (*Tel Aviv University, Tel Aviv, Israel*)

K. Zaman (*ICDDR, Dhaka, Bangladesh*)

Robert F. Bargatzke (*Consultant, Takeda Vaccines Inc., Bozeman, Montana, USA*)

Hugues Bogaerts (*Consultant, Takeda Vaccines, Belgium*)



PROVISIONAL CONFERENCE PROGRAMME OF CONFIRMED PRESENTATIONS

'WHO viewpoint on rotavirus vaccines and norovirus vaccines'

Speaker to be confirmed
(WHO, Geneva, Switzerland)

'Combined rotavirus VP6 and norovirus VLP vaccine'

Timo Vesikari
(University of Tampere, Tampere, Finland)

'Rotavirus vaccine studies: Past, present and future'

K. Zaman
(ICDDR, Dhaka, Bangladesh)

'Challenges in developing a norovirus vaccine and recent approaches in addressing those challenges'

Sean Tucker
(Vaxart Inc., South San Francisco, California, USA)

'The benefits of rotavirus vaccination: Lessons learned from European data 2006-2017'

D. Poelaert, B. Standaert, V. Singh, V. Vetter and B. Benninghoff
(GSK Vaccines, Wavre, Belgium)

'Clinical development of a bivalent norovirus VLP vaccine candidate'

Jim Sherwood, Taisei Masuda, Inge Lefevre and Astrid Borkowski
(Takeda Pharmaceuticals International AG, Zurich, Switzerland)

'Evaluation of vaccine preventable disease surveillance system in Haryana state, India 2015'

Prasoon Sheoran
(Directorate of Health & Family Welfare, Dehradun, India)

'Rotavirus VP6 vaccine induced cell mediated immunity'

Suvi Heinimä
(University of Tampere, Tampere, Finland)

'Rotavirus vaccines: Title to be confirmed'

Nigel A. Cunliffe
(University of Liverpool, Liverpool, UK)

'A review of recommendations for rotavirus vaccination in Europe'

D. Poelaert, P. Pereira, Robert Gardner, B. Standaert and B. Benninghoff
(GSK Vaccines, Wavre, Belgium)

'A prospective study on the importance of Norovirus as a cause of AGE among children in four countries in Latin America and Asia (2014-17)'

Margarita Riera-Montes¹, Marco Aurelio Safadi², Lulu Bravo³, Auchara Tangsathapornpong⁴, U. Thisyakorn⁵, Rosanna Lagos⁶, Alexandre Linhares⁷, Maria Rosario Capeding⁸, Olarn Prommalikit⁹, Miguel O'Ryan¹⁰ and Thomas Verstraeten¹
(¹ P95 Epidemiology and Pharmacovigilance Services, Leuven, Belgium; ² Department of Pediatrics, Santa Casa de São Paulo School of Medical Sciences, Brazil; ³ National Institutes of Health, University of the Philippines, Manila, Philippines; ⁴ Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, Thailand; ⁵ Chulalongkorn University, Bangkok, Thailand; ⁶ Centre for Vaccine Development, Hospital de Niños Roberto del Río, Santiago, Chile; ⁷ Virology Section, Instituto Evandro Chagas, Belem, Brazil; ⁸ Department of Health, Research Institute for Tropical Medicine, Muntinlupa City, Philippines; ⁹ Department of Pediatrics, HRH Princess Maha Chakri Sirindhorn Medical Centre, Nakhon-Nayok, Thailand; ¹⁰ Institute of Biomedical Sciences, Universidad de Chile, Santiago, Chile)

'Norovirus surveillance (two year family surveillance) in Chile'

Miguel O'Ryan
(Faculty of Medicine, University of Chile, Santiago, Chile)

'Emerging rotavirus G8 strains in Chile'

Miguel O'Ryan
(Faculty of Medicine, University of Chile, Santiago, Chile)

'Serological imprinting shapes norovirus vaccine responses'

Lisa C. Lindesmith¹, Jonathan R. McDaniel², Scott A. Kerr², Paul D. Brewer-Jensen¹, Michael L. Mallory¹, Gregory C. Ippolito³, John J. Blazeck², Daniel R. Boutz⁴, George Georgiou² and Ralph S. Baric¹
(¹ Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA; ² Department of Chemical Engineering, University of Texas at Austin, Texas, USA; ³ Department of Molecular Biosciences, University of Texas at Austin, Texas, USA; ⁴ Institute for Cellular and Molecular Biology, The University of Texas at Austin, Texas, USA)

'Title to be confirmed'

Yuri Vasiliev
(State Research Institute of Ultrapure Biological, St. Petersburg, Russian Federation)

'Immunotypes: A genomics approach to understand norovirus immunity'

Gabriel I. Parra
(Division of Viral Products, CBER, FDA, Silver Spring, Maryland, USA)

'Replication of human norovirus in human intestinal enteroids'

Jan Vinjé¹, Esther K. Morantz², Hannah Browne³, Khalil Ettayebi⁴, Xi-Lei Zeng⁴, Mary K. Estes⁴ and Veronica Costantini¹
(¹ Centers for Disease Control, Atlanta, Georgia, USA; ² Synergy America Inc, Atlanta, Georgia, USA; ³ Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA; ⁴ Baylor College of Medicine, Houston, Texas, USA)

'The burden of medically attended acute gastro-enteritis due to norovirus in Japan: Results from a database analysis'

C. Chang¹, M. Sakaguchi¹, T. Verstraeten² and J. Weil³
(¹ Takeda Pharmaceutical Company, Osaka, Japan; ² P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium; ³ Takeda Vaccines Inc., Bozeman, Illinois, USA)

'Post-vaccination oral rotavirus vaccine shedding is not associated with vaccine immunogenicity or efficacy among infants in Bangladesh'

Benjamin Lee¹, Abdul Kader², Sean A. Diehl¹, E. Ross Colgate¹, Marya Carmolli¹, Muhammad Ikhtear Uddin², Salma Sharmin², Shahidul Islam², Taufiqur Rahman Bhuiyan², Dorothy M. Dickson¹, Mami Taniuchi³, William A. Petri³, Firdausi Qadri², Rashidul Haque² and Beth D. Kirkpatrick¹
(¹ University of Vermont, Burlington, Vermont, USA; ² International Center for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; ³ University of Virginia, Charlottesville, Virginia, USA)

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 18th May 2018. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 18th May 2018.

‘Safety and immunogenicity of a parenteral P2-VP8 subunit rotavirus vaccine’

Michelle J. Groome^{1,2}, Anthonet Koen^{1,2}, Alan Fix³, Lee Fairlie⁴, Julie Morrison⁵, Nicola Page^{6,7}, Lisa Jose^{1,2}, Shabir A. Madhi^{1,2,6}, Monica McNeal⁸, Len Dally⁹, Iksung Cho³, Maureen Power³, Jorge Flores³ and Stanley Cryz³
 (1 Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, South Africa; 2 Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, South Africa; 3 PATH, Seattle, Washington, USA; 4 Wits Reproductive Health and HIV Institute, University of the Witwatersrand, South Africa; 5 Family Clinical Research Unit, Stellenbosch University, South Africa; 6 National Institute for Communicable Diseases, National Health Laboratory Service, South Africa; 7 Department of Medical Virology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa; 8 Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, USA; 9 The Emmes Corporation, Rockville, USA)

‘A randomized Phase I/II study to evaluate safety and reactogenicity of a single dose of lyophilized live attenuated pentavalent (G1-G4 and P1[8]) heat-stable rotavirus vaccine (HSRV), in healthy adult volunteers; followed by evaluation of the safety, reactogenicity and immunogenicity of a 3-dose series in infants age 6 to 8 weeks’

K. Zaman¹, Ajit pal Singh², W.A. Khan¹, M. Karim¹, Vibhu Kanchan², Asma Aziz¹, Warda Haque¹, Syed Khalid Ali², Michelle Goveia³, Susan Kaplan³, Davinder Gill² and John D. Clemens¹
 (1 icddr, Dhaka, Bangladesh; 2 MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., New Delhi, India; 3 Merck & Co. Inc., Kenilworth New Jersey, USA)

‘Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: A re-analysis of a clinical trial of monovalent rotavirus vaccine in Dhaka, Bangladesh (PROVIDE) and a simulation study’

Elizabeth T. Rogawski, James A. Platts-Mills, E. Ross Colgate, Rashidul Haque, K. Zaman, William A. Petri Jr. and Beth D. Kirkpatrick
 (University of Virginia, Charlottesville, Virginia, USA)

‘Strategies to improve rotavirus vaccine impact and effectiveness during the second year of life in Blantyre, Malawi: A mathematical modeling study’

Virginia E. Pitzer¹, Aisleen Bennett^{2,3}, Naor Bar-Zeev^{2,3}, Benjamin A. Lopman⁴, Umesh D. Parashar⁵ and Nigel A. Cunliffe³
 (1 Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, Connecticut, USA; 2 Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi; 3 Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; 4 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; 5 Epidemiology Branch, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA)

‘The changing epidemiology of rotavirus diarrhea:

Results from the Global Burden of Disease study 2016’

Christopher Troeger, Ibrahim Khalil, Puja Rao, Manny Garcia, Shijun Cao, Simon Hay and Robert Reiner
 (Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA)

‘Norovirus VLP and rotavirus VP6 nanoparticles as a combination vaccine candidate’

Vesna Blazevic
 (Vaccine Research Center, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland)

‘Norovirus-specific T cell responses in VLP immunized mice are targeted both to conserved and variable domains of capsid VP1’

Maria Malm, Kirsi Tamminen, Timo Vesikari and Vesna Blazevic
 (Vaccine Research Center, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland)

‘Norovirus VLP induced type-specific and cross-reactive immunity’

Kirsi Tamminen, Maria Malm, Suvi Heinimäki, Timo Vesikari and Vesna Blazevic
 (Vaccine Research Center, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland)

‘Re-engineering the rotavirus genome to express the norovirus capsid protein’

John T. Patton
 (Indiana University, Bloomington, Indiana, USA)

‘Conformational occlusion of conserved GII.4 blockade antibody epitopes: A novel mechanism of human norovirus immune evasion’

Lisa C. Lindesmith¹, Michael L. Mallory¹, Kari Debbink², Eric F. Donaldson¹, Paul D. Brewer-Jensen¹, Excel W. Swann¹, Timothy P. Sheahan¹, Rachel L. Graham¹, Martina Beltramello³, Davide Corti³, Antonio Lanzavecchia^{4,5} and Ralph S. Baric¹
 (1 Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA; 2 Department of Natural Sciences, Bowie State University, Bowie, Maryland, USA; 3 Humabs BioMed SA, Bellinzona, Switzerland; 4 Institute for Research in Biomedicine, Bellinzona, Switzerland; 5 Institute of Microbiology, Zurich, Switzerland)

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 18th May 2018. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 18th May 2018.

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 18th May 2018. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 18th May 2018.

REGISTRATION

Delegates should register for NRVW 2018 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (payment in £ Pounds Sterling) should be sent to the NRVW 2018 Conference Manager – Caroline Sumner at Meetings Management. The NRVW 2018 Conference Registration Desk will be open from 8.00am on Monday 4th June 2018.

Delegates can also register securely on-line at:
www.meetingsmanagement.com/nrvw_2018

VENUE & ACCOMMODATION

NRVW 2018 will be held at:

CHUV, Lausanne, Switzerland

Accommodation: there are numerous hotels in Lausanne to suit most budgets. For information details on accommodation in Lausanne and other useful information, please visit:

<http://www.lausanne-tourisme.ch/en/>

Please note that the NRVW 2018 conference organizers will not be recommending any specific hotels in Lausanne.

June is a busy time in Lausanne and it is recommended that NRVW 2018 delegates book their accommodation without delay.

PUBLICATION

A USB storage device containing the final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

TABLE TOP EXHIBITION

Table Top Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. If you are registering for the conference, you can reserve a table for £1995. If you do not wish to attend the conference sessions, you can reserve a table for £3995 (includes admission to all meals/receptions by one company representative).

PLEASE NOTE: If you wish to have additional representatives on your table top exhibit there will be an additional charge for catering levied per head. Please contact the Conference Manager for this additional price.

Please make your bookings and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Table Top Exhibition facilities at NRVW 2018 should be directed to John Herriot at Meetings Management (jherriot@meetingsmgmt.u-net.com).

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the NRVW 2018 delegate pack is priced at £425. Please make your booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion services at NRVW 2018 should be directed to John Herriot at Meetings Management (jherriot@meetingsmgmt.u-net.com).

PLEASE NOTE: Literature for distribution to NRVW 2018 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at NRVW 2018. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAMME

The NRVW 2018 Scientific Advisory Panel and the NRVW 2018 Conference Organizers reserve the right to alter any part of the published provisional conference programme if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The provisional programme published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstract booklet, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization's library up to date. The cost of providing this non-attendee package is £395 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner, NRVW 2018 Conference Manager:

NRVW 2018 Conference Secretariat, Meetings Management

Forge Cottage, Bowlhead Green, Godalming, Surrey GU8 6NW, United Kingdom.

Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516

E-mail: csumner@meetingsmgmt.u-net.com

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 18th May 2018. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 18th May 2018.

Please tick appropriate boxes and write clearly in BLOCK CAPITALS or type.

Surname First Name Title
 Organization Address

 Postcode
 Country Telephone Fax
 E-mail (plain type or print):
 If you are an EC business please state your VAT registration number:
 Disabled (please state any special needs): Special diet (please state requirements):

REGISTRATION FEES

Speaker/Delegate Registration Fees: (Please tick appropriate section)	(NOTE THAT FEES ARE IN UK £ STERLING)	DELEGATE REGISTRATION FORMS NOT DULY & FULLY COMPLETED WILL NOT BE VALID Amount Due (£ Sterling)
☐ Speaker Registration (submitted oral/poster papers) (Payment must be received before Friday 23rd March 2018)	£645.00	£
☐ Reduced Early Bird Registration (Payment must be received before Friday 23rd March 2018)	£775.00	£
☐ Full Registration (Payment received after Friday 23rd March 2018)	£895.00	£
☐ Student Registration	POA	£

Table Top Exhibits/Delegate Pack Inserts

☐ Table Top Exhibit (If registering for one of the four options above)	£1600.00	£
☐ Table Top Exhibit (I am NOT registered to attend)	£3600.00	£
☐ Delegate Pack Insert	£425.00	£

PLEASE NOTE: The above payments for Table Top Exhibits are for 1 company representative only. If you require additional representatives please contact the Conference Manager for a price.

For those Unable to Attend

☐ Set(s) of NRVW 2018 materials @ £395.00 (per set) £

Total Amount Payable £

Registration fees include admission to all conference sessions, morning and afternoon refreshments and lunches on the 4th, 5th and 6th June 2018.

PAYMENT

- ☐ I enclose a cheque for £..... made payable to **Meetings Management**. (Delegates registering from outside the UK must ensure that cheques are drawn on a London Bank. Please quote **NRVW 2018** on the reverse of the cheque.)
- ☐ I have made a payment by bank transfer (quoting **NRVW 2018** on the transfer documentation) to Barclays Bank, Barclays Business Centre, Guildford Branch, PO Box 33, Guildford, Surrey GU1 3AN, UK:
- UK Pounds Sterling Account: Meetings Management 0040614335,
 IBAN GB02BARC20353540614335 SWIFTBIC BARCGB22
- US Dollar Account: Meetings Management 53209211,
 IBAN GB77BARC20353553209211 SWIFTBIC BARCGB22
- Euro Account: Meetings Management 59179600,
 IBAN GB02BARC20353559179600 SWIFTBIC BARCGB22

All transfer charges must be paid by the sender. Delegates paying by this method are requested to send the Conference Manager a copy of the bank transfer. **Payments made by bank transfer must have £15.00 added to the total. PLEASE NOTE THAT IT WILL NOT BE POSSIBLE TO PAY REGISTRATION FEES BY BANK TRANSFER AFTER FRIDAY 11TH MAY 2018. LATE PAYMENT AFTER FRIDAY 11TH MAY 2018 MUST BE MADE BY CREDIT CARD (VISA/MASTERCARD/AMEX).**

☐ I would like to pay £..... by credit card (VISA/MasterCard/American Express only accepted).

Card no. ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 3 Digit Security Code (AMEX: 4 Digits)
 Expiry Date Registered Card Address

Please remember that any remittance sent but not received by the time of the conference must be paid again at the Registration desk: we will refund you after the conference. Cancellations received before Friday 20th April 2018 will be refunded in full less an administrative charge of £225 per person. Refunds will not be possible if a cancellation is received after Friday 20th April 2018. Substitutions can be made at any time prior to the conference. Please inform the Conference Manager of any changes. We strongly advise that delegates purchase travel insurance to cover any unforeseen circumstances and protect against loss of hotel deposits and registration fees.

Signature Date

PLEASE RETURN THIS FORM TO:

NRVW 2018 CONFERENCE SECRETARIAT, MEETINGS MANAGEMENT
 Forge Cottage, Bowlhead Green, Godalming, Surrey GU8 6NW, United Kingdom
 Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: csumner@meetingsmgmt.u-net.com